PBLA Stock Performance, Insider Transaction and News

PBLA - Panbela Therapeutics, Inc.

Market Cap	5.35M	P/E	-	EPS this Y	98.30%	Ern Qtrly Grth	-
Income	-34.4M	Forward P/E	-0.40	EPS next Y	11.30%	50D Avg Chg	-55.00%
Sales	-	PEG	-	EPS past 5Y	-	200D Avg Chg	-97.00%
Dividend	N/A	Price/Book	0.40	EPS next 5Y	-	52W High Chg	-100.00%
Recommedations	2.00	Quick Ratio	0.22	Shares Outstanding	4.85M	52W Low Chg	5.00%
Insider Own	0.00%	ROA	-191.05%	Shares Float	4.85M	Beta	0.78
Inst Own	0.16%	ROE	-	Shares Shorted/Prior	106.97K/46.36K	Price	1.89
Gross Margin	-	Profit Margin	-	Avg. Volume	989,690	Target Price	252.50
Oper. Margin	-	Earnings Date	May 2	Volume	114,133	Change	-2.58%

Healthcare | Biotechnology | United States

About Panbela Therapeutics, Inc.

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Panbela Therapeutics, Inc. News

04/22/24	Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
04/18/24	Panbela Announces Poster Presentation at American Association for Cancer Research:
04/16/24	Panbela Announces Transfer to OTCQB Market
03/26/24	Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
03/12/24	Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
02/15/24	Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
02/01/24	Panbela Announces Closing of Approximately $9.0 Million Public Offering
01/30/24	Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
01/29/24	Panbela Announces Pricing of Approximately $9.0 Million Public Offering
07:00 AM	Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
01/18/24	Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
01/16/24	Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024
12/21/23	Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-Market
12/18/23	Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
12/04/23	Panbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors
11/29/23	Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
11/09/23	Panbela Provides Business Update and Reports Q3 2023 Financial Results
11/03/23	Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market
11/02/23	Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
10/31/23	Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101

PBLA Chatroom

Barney2 Posted - 1 day ago

$PBLA 💩💩 strong sell loses 90% a month dilutes shares regularly!

Hankies Posted - 1 day ago

$PBLA Voila.

Hankies Posted - 1 day ago

$PBLA Enjoy looking at the green from yesterday. It will be gone on open. Never holds.

Hankies Posted - 2 days ago

$PBLA So, shit news and it makes gains. I guess we wait for the -40% tomorrow.

EVOTZ Posted - 2 days ago

$PBLA more dilution coming

EVOTZ Posted - 2 days ago

$PBLA https://seekingalpha.com/news/4091892-panbela-therapeutics-announces-delay-of-expected-data-from-pancreatic-cancer-treatment-trial

Bhealthy Posted - 2 days ago

$PBLA Delay in trial data until 2025! Lol 😂 They have no way to continue to pay for their trials. This is done!

Barney2 Posted - 2 days ago

$PBLA 💩💩💩💩

SilentRider1 Posted - 3 days ago

$PBLA otcqb

Bigloser75 Posted - 4 days ago

$PBLA the only way for the stock is company spend a million dollar buy back and getting back to Nasdaq

Bigloser75 Posted - 4 days ago

$PBLA if we all start to short this. We will get out money back quickly.

Bigloser75 Posted - 4 days ago

$PBLA this is the stock made for shorts. So I will suggest after reverse split. Open a short position for this everyone. Get a new broker.

Bigloser75 Posted - 4 days ago

$PBLA whoever had short positions if this 3 years ago for 100 dollars. Now will be a billion dollars

Tungtran1 Posted - 5 days ago

$PBLA this stock I think game over we loose 100%

Bigloser75 Posted - 6 days ago

$PBLA ok. They already have less than 490 share holders. Not sure if it legal to reverse split without out my vote.

Bigloser75 Posted - 6 days ago

$PBLA I have a 5 dollar average I am thinking average down

bamarusty Posted - 6 days ago

$PBLA another reverse split coming around 5/5

Bigloser75 Posted - 1 week ago

$PBLA if they stayed above 4 dollars just little longer, without the offering, they would had more share holders and stayed in nasdaq

Bigloser75 Posted - 1 week ago

$PBLA you need put some money you scam people, and buy back some shares, and go back to 4 dollar, maybe karma will start changing

Bigloser75 Posted - 1 week ago

$PBLA it was good a stock until you did the scam offering and trying to wipe out everyone, now you lost your nasdaq, i lose all my money,

Lay1a Posted - 1 week ago

$PBLA No reason why this stock will show any support. I thought I would purchase at 55c for a trade but changed my mind to 50c and now will not purchase and will just monitor.

Hankies Posted - 1 week ago

$PBLA say goodbye to yesterday's gains.

Bigloser75 Posted - 1 week ago

$PBLA can you go to 90 cents make it more interesting for people to buy

Bigloser75 Posted - 1 week ago

$PBLA can you short in otc

TheGrowthSensei Posted - 2 weeks ago

$PBLA 😂😂😂 been this way for so long I often forget. No point taking that change for a takeaway

EVOTZ Posted - 2 weeks ago

$PBLA poster presentation tomorrow at AACR in San Diego. Interim readout of ASPIRE results in the next 2 months.

Hankies Posted - 2 weeks ago

$PBLA WTF is with these guys? They literally dead? No PR. Bankruptcy next leg down after delisting. Amy one have any idea what their plan is? Serious question.

Happy_Analyzer Posted - 2 weeks ago

$PBLA do they still have an office next to the UPS store?

Bigloser75 Posted - 2 weeks ago

$PBLA the people managing this stock is the amateur. Could be that Barney idiot dude. I think he just got fired. That is why he turns to a bear

Bigloser75 Posted - 2 weeks ago

$PBLA market maker do you know how to manage a stock ? Back rules you broke it

Analyst Ratings

HC Wainwright & Co.	Buy	Apr 2, 24
Roth MKM	Buy	Mar 27, 24
Roth MKM	Buy	Feb 5, 24

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
GOLDMAN SACHS GROUP INC	10% Owner 10% Owner	Nov 08	Sell	0.71	72,874	51,741	397,954	11/13/23